Erlotinib tablet- Effective Medication To cure Lung Cancer

Erlotinib tablet is one of the most common drugs used for the treatment of lung cancer. It helps to stop or slow the growth of cancer cells in the lungs.

How to use erlotinib tablet?

You can take this medicine by mouth before 1 or 2 hours before or after the meal when your stomach is empty. In a better direction, takes your doctor’s advice. Before taking this medicine, aware your doctor about your previous history and the medicines you are taking whether they are prescription medicine or herbal products.  You should know that taking medicine on the fixed time will help you to stop the growth of cancer cells in your lungs. It is very important to take erlotinib tablets regularly once a day according to the doctor’s advice.

How erlotinib is right now utilized in the center?

Erlotinib tablets was first endorsed by the United States Food and Drug Administration (FDA) for use in patients with cutting edge non-little cell lung malignant growth that had backslid after at any rate one other sort of treatment. Patients taking erlotinib 150 mg ordinarily endure the medication very well. The most widely recognized reactions are a skin rash and the runs.

How long this medicine works?

Erlotinib is profoundly viable in the subset of patients conveying EGFR changes. Be that as it may, even these patients will in the end start to show the movement of their disease after around a year of erlotinib treatment. This is because of the advancement of protection from the medication in the lingering malignant growth cells.

Side effects of Erlotinib Tablets- 

The most common symptoms while taking this medicine includes:

• Diarrhea
• Dry skin
• Muscle pain
• Mouth sores
• Unusual eyelash growth
• Eye dryness
• Redness of the eye

Diarrhea is the most common side effect of this medicine. Consult your doctor right away if you face any serious side effects that are:

• Kidney problems
• Signs of liver disease
• Loss of appetite
• Dark urine
• Abdominal pain
• Dizziness
• Fainting

This medicine can cause a mild rash as well so you don’t have to worry if you face any rash.

Precautions:

Before taking this medicine, tell your doctor if you are allergic to any acid, if you are pregnant, or if you are facing any other diseases like diabetes and blood pressure issues. This medicine can cause bleeding in the stomach as well. This tablet is not established for patients younger than 18 years old. Avoid grapefruit or grapefruit juice while taking this medicine. Avoid this medicine if you are planning to conceive a baby because it may be harmful to the unborn baby.

What if you miss a regular dose intake?

If you missed a dose, take it as soon as possible but only on an empty stomach. Do not take any extra medicine to overdose yourself. If you overdose the medicine, immediately calls your doctor to lower the risk of side effects.

Conclusion:

This medicine is one of the most effective lung cancer medications which doctors highly recommended. Kindly take care of yourself and eat healthy to stay healthy.

Read:- Indications and dosage of Erlotinib tablets

Metastatic Non Small cell lung cancer treatment guidelines

Introduction to lung cancer:

• Lung cancer arises from cells in the lung that have grown abnormally and multiplied to form a lump or tumour.
• Non-small-cell lung cancer (NSCLC) is a type of lung cancer, which is differentiated from small-cell lung cancer (SCLC) because of the way the tumour cells look under a microscope. The three main types of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell (undifferentiated) carcinoma of the lung, all are described below. They are diagnosed in the same way but may be treated differently.
• Lung cancer is the third most common cancer in Europe; NSCLC represents 85–90% of all lung cancers. Smoking is the biggest risk factor for the development of lung cancer.

Diagnosis of NSCLC: 

Lung cancer may be suspected if a person has symptoms such as persistent cough or chest infection, breathlessness, hoarseness, chest pain or coughing up blood. Other symptoms may be fever, appetite loss, unexplained weight loss and fatigue.
Following a clinical examination, your doctor will arrange for an x-ray and/or computed tomography (CT) scan (or might use other technologies, such as positron emission tomography [PET] CT scan or magnetic resonance imaging [MRI]) to evaluate the position and extent of the cancer. Examination and observation of a biopsy will confirm a diagnosis of the NSCLC.

Treatment options for NSCLC: 

Chemotherapy: The utilization of anticancer medications in order to destroy the cancerous cells. Chemotherapy should be taken alone or with the other treatments.

Targeted therapy: newer medications that function by blocking the signals that indicate cancerous cells to develop. Gefitinib and Erlotinib are the most promising drugs for the treatment of NSCLC.

• Gefitinib: The FDA approved Gefitinib 250 mg in May 2003 for non-small cell lung cancer (NSCLC). It was approved as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies. i.e. as a third-line therapy.
• Erlotinib: The U.S. Food and FDA approved erlotinib 150 mg for the treatment of locally advanced or metastatic non-small cell lung cancer that has failed at least one prior chemotherapy regimen.

Immunotherapy: a sort of treatment basically designed in order to boost the body’s natural defences to fight off cancer.
check- what does immunotherapy do for lung cancer patient

Radiotherapy: the utilization of measured doses of the radiation in order to damage the cancerous cells and prevent them from growing.
Combinations of different treatment types are frequently offered based on the stage and type of NSCLC and on the patient’s condition and comorbidities (additional diseases or disorders experienced at the same time).

Types of Stages: 

Cancer is ‘staged’ according to tumour size, involvement of regional lymph nodes and whether it has spread outside the lung to other parts of the body. This information is used to help decide the best treatment.

Early-stage (stage I-II) NSCLC:

• Surgery is kind of the main treatment for the initial-stage NSCLC.
• Chemotherapy may be given after surgery (adjuvant chemotherapy) in patients with Stage II and Stage III NSCLC and in some patients with Stage IB disease. 
• Radiotherapy (either stereotactic ablative radiotherapy [SABR] or conventional radiotherapy) is an alternative to surgery in patients who are unable or unwilling to have surgery. 
• Radiotherapy may be given after surgery (adjuvant radiotherapy) in patients with Stage II and Stage III NSCLC. 

Locally advanced (Stage III) NSCLC:

Treatment for locally advanced NSCLC is likely to involve different types of therapy (multimodal therapy). If it is possible to remove the tumour (i.e. the tumour is resectable), treatment options can include:

• Induction therapy consisting of chemotherapy with or without radiotherapy, followed by surgery.
• Surgery followed by adjuvant chemotherapy and/or radiotherapy.
• Chemoradiotherapy (i.e. chemotherapy and radiotherapy given at the same time or sequentially).
• The type of treatment and sometimes the sequence of treatments offered to patients with resectable Stage III NSCLC will depend on the general health of the patient and any comorbidities, as well as the extent and complexity of the surgery required to remove the tumour.
• In unresectable Stage III NSCLC, chemoradiotherapy is the preferred treatment. Alternatively, chemotherapy and radiotherapy can be given sequentially (i.e. one after the other) in patients unable to tolerate concurrent treatment.
• Immunotherapy may be offered to some patients with unresectable locally advanced NSCLC following treatment with chemoradiotherapy.

Metastatic (Stage IV) NSCLC: 

NSCLC is referred to as metastatic or Stage IV disease when it has spread beyond the lung which was initially affected.

• It is rarely possible to remove Metastatic Non-Small Cell Lung Cancer with surgery or to treat it radically with radiotherapy.
• Intravenous chemotherapy with a two-drug combination (with or without the addition of the targeted therapy called bevacizumab) is the main treatment for patients with metastatic NSCLC. 
• The choice of drugs used will largely depend on the general health of the patient and the histological subtype of the tumour.
• Patients whose tumours express relatively high levels of programmed death-ligand 1 (PD-L1) protein (determined by molecular testing using a tumour biopsy) may receive first-line immunotherapy with pembrolizumab. 
• Patients whose tumours contain specific mutations (alterations) to the epidermal growth factor receptor (EGFR), BRAF, anaplastic lymphoma kinase (ALK) or ROS1 genes (determined by molecular testing using a tumour biopsy) are best treated with oral targeted therapies given continuously.

Subtypes of the NSCLC: The three main histological subtypes of NSCLC are:

Adenocarcinoma: Approx 40% of all the lung cancers are adenocarcinomas. These tumours start in mucus-producing cells that line the airways.

Squamous cell carcinoma (SCC): Approximately 25–30% of all the lung cancers are SCC. This sort of cancer develops in cells that line the airways and is usually caused by smoking.

Large cell carcinoma: This sort makes up about 10–15% of all the lung cancers. It gets its name from the way that the cancer cells look when they are observed Or examined under the microscope.

Read:- Small cell lung cancer treatment-related guidelines

How effective is erlotinib against lung cancer?

In lung cancer treatment erlotinib has been shown quite effective in patients who carried EGFR mutations. but appears to be more effective in patients with EGFR mutations. In November 2005, this lung cancer medication was also approved by FDA for pancreatic cancer.

Specifications of Erlotinib 150 mg:

Following terms of Erlotinib tablets represents that, in what ways this medication is effective.

• Erlotinib is a selective EGFR tyrosine kinase inhibitor.
• The medication reduces the autophosphorylation of Epidermal Growth Factor Receptor in intact tumor cells and the proliferation of the EGFR dependent cell, which blocks the initiation of the cellular cycle in the G1 phase.
• This medication was approved by the FDA (Food and Drug Administration) for the treatment of locally advanced or Metastatic Non-Small Cell Lung Cancer in 2004.
• Studies show that monotherapy would be useful with this drug and also more active for patients with NSCLC and mutated EGFR.
• The use of erlotinib 150 mg has been shown to be quite effective in the treatment of NSCLC with mutated EGFR.
• Patients with EGFR-activating mutations, such as L858R in exon 21 and deletions in exon 19, show improvement in symptoms and a higher response rate with the use of erlotinib.
• Investigation of the EGFR mutation is essential for the decision to initiate the use of erlotinib, and its absence is justified only by the impossibility of performing it, such as, for example, due to scarcity of material.
• This mutation was found with greater frequency in non-smoking patients with the adenocarcinoma histological subtype, which, presented with greater sensitivity to gefitinib and erlotinib in one study.
• Elderly patients also benefited from the use of erlotinib, but at the cost of greater toxicity, even though it is tolerable in most cases.
• The subgroup of patients include Asian patients, of the female gender, with adenocarcinoma subtype, and non-smokers are at the greatest benefit from the medication.
• It also includes those who are at the greatest prevalence of EGFR mutations.
• The KRAS gene mutation showed an inverse relation with the response to erlotinib, as well as with the non-coexistence with the EGFR mutation. 
• Treatment with erlotinib in patients with mutated KRAS resulted in worse survival in comparison with the control group, suggesting a possible reduction of responsiveness to erlotinib in the presence of the said mutation. 
• Overall response rate (OR) is approximately 50%, which is far better than the standard second-line chemotherapy
• One-year survival is similar to standard second-line therapy. 
• Progression-free survival similar to standard second-line therapy. 
• And overall survival is also similar to standard second-line therapy. 

Read:- Why Doctors Are Using Erlotinib 150 mg in Lung Cancer Treatment

How is stage 4 lung cancer diagnosed?

In stage 4, cancer has spread to other parts of the body, such as the liver or bones.
As a consequence, many patients go to their healthcare providers when the disease is at an advanced stage when symptoms become more troublesome and persist.

Symptoms to watch out for include:

• Persistent cough
• A change in a persistent cough
• Shortness of breath
• Loss of appetite
• Fatigue
• Loss of weight
• Aches or pains while breathing or coughing. 
• Coughing up phlegm (sputum) with signs of blood. 

Diagnosis helps in the detection of the disease. In order to obtain an accurate and precise diagnosis, analysis of cancerous cell tissue is very crucial. There are a variety of tests available in order to diagnose lung cancer.

Bronchoscopy: It is a kind of visual examination of the trachea and internal parts of the lungs. Specimens of tissue can be taken from inside the patient lungs in order to gather cells for analysis.
Cytology: In this, a sample of sputum is taken to in order to specify the diagnosis and the type of lung cancer
Needle biopsy: In order to obtain cells for analysis, needle biopsy takes place along with a CT scan.

Medications for Lung Cancer:

Treatment options vary depending on the type and stage of cancer in addition to its size, position in the lung, whether it has reached to the other parts of the body. And also the overall physical health of the patient plays a major role.
In general, the treatment options for NSCLC are:

• Surgery: Patients with early-stage, localised Non Small Cell Lung Cancer may be successfully treated using surgery. Approximately, up to 70% of patients survive for at least five years after diagnosis if treated at this stage, with a proportion of these patients being cured.

• Radiotherapy: For patients with un-operated on cancer, radiotherapy may be offered alone or in combination with chemotherapy.

• Treatment with the help of radiotherapy plays a key role in order to provide control and relief of the symptoms of lung cancer.

• Chemotherapy: Most of the cases of Non-Small Cell Lung Cancer diagnosed at an advanced stage 1, and in this stage, the cancer has already spread to the other parts and in such cases, surgery could be difficult. 

• Biological (targeted) Therapy: Targeted therapy is relatively a new approach to cancer treatment that targets specific biological processes often essential to tumour growth.

• Erlotinib 150 mg & Gefitinib 250 mg is quite popular amongst the doctors for the treatment of patients with non-small cell lung cancer. 

• As a targeted therapy, Erlotinib 150 mg is available at the lowest price. Erlotinib tablets should be taken orally.